DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $45,000 | -30.8% | 1,524 | -24.7% | 0.00% | – |
| Q1 2022 | $65,000 | -83.8% | 2,024 | -77.6% | 0.00% | -100.0% |
| Q4 2021 | $402,000 | +219.0% | 9,024 | +261.0% | 0.00% | +100.0% |
| Q3 2021 | $126,000 | -73.5% | 2,500 | -58.7% | 0.00% | -66.7% |
| Q2 2021 | $475,000 | +691.7% | 6,053 | +474.8% | 0.00% | – |
| Q1 2021 | $60,000 | -33.3% | 1,053 | -1.6% | 0.00% | -100.0% |
| Q4 2020 | $90,000 | +125.0% | 1,070 | -53.8% | 0.00% | – |
| Q4 2019 | $40,000 | +14.3% | 2,316 | 0.0% | 0.00% | – |
| Q3 2019 | $35,000 | -27.1% | 2,316 | 0.0% | 0.00% | – |
| Q2 2019 | $48,000 | -11.1% | 2,316 | 0.0% | 0.00% | – |
| Q1 2019 | $54,000 | +12.5% | 2,316 | 0.0% | 0.00% | – |
| Q4 2018 | $48,000 | – | 2,316 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |